

# Pharmaceutical Therapeutic Categories Outlook

The \$355B worldwide pharmaceutical industry has terrific secular growth prospects, driven mostly by new products derived from rich R&D pipelines. New research tools for finding promising targets and strategies for reducing development time bolster the long-term outlook. These factors more than offset near-term uncertainties in the regulatory review process and debate on the need for prescription drug benefits. This comprehensive study forecasts trends in the major therapeutic drug categories through 2005. Each category is defined by therapeutic need, market size, growth outlook, major new compounds in development, and an assessment of individual company prospects. As shown below, the companies predicted to lead in “Market Share,” “Total Therapeutic Positions,” and “Leading Therapeutic Positions” are similar to last year. However, a new group of companies is poised for “Market Share Gain” through 2005. This analysis reaffirms our top picks in the group: **Bristol-Myers Squibb, Eli Lilly, Pfizer** and **Pharmacia**. We also like **Elan, Forest Labs** and **King Pharmaceuticals** in the mid-cap Rx segment.

## WHICH COMPANIES WILL LEAD INDUSTRY THROUGH 2005?

Market Share	Market Share Gain	Total Therapeutic Positions	Leading Therapeutic Positions
GlaxoSmithKline	Eli Lilly	Pfizer (12)	GlaxoSmithKline (4)
Pfizer	Novartis	Pharmacia (11)	American Home Products (3)
Merck	Amgen	GlaxoSmithKline (9)	Bristol-Myers Squibb (2)
Bristol-Myers Squibb	Johnson & Johnson	Johnson & Johnson (9)	Pfizer (2)
Aventis	American Home Products	Merck (9)	

## SG COWEN PHARMACEUTICAL UNIVERSE

Company	Symbol	Stock Rating	9/27/01 Price	EPS		P/E	
				2001E	2002E	2001E	2002E
Abbott Laboratories	ABT	1	\$50	\$1.89	\$2.26	26X	22X
American Home Products	AHP	2	57	2.18	2.60	26	22
Amgen	AMGN	2	57	1.18	1.35	48	42
Bristol-Myers Squibb	BMY	1	53	2.39	2.60	22	20
Elan	ELN	2	48	1.90	2.30	25	21
Eli Lilly	LLY	1	79	2.80	2.85	28	28
Forest Labs	FRX	1	71	1.60	1.89	44	38
Genentech	DNA	2	42	0.75	0.95	56	44
GlaxoSmithKline	GSK	2	53	2.11	2.40	25	22
Johnson & Johnson	JNJ	2	54	1.93	2.20	28	25
King Pharmaceuticals	KG	1	42	1.01	1.35	41	31
Merck	MRK	2	63	3.15	3.45	20	18
Pfizer	PFE	1	39	1.30	1.60	30	24
Pharmacia	PHA	1	39	1.74	2.06	22	19
Schering-Plough	SGP	2	35	1.65	1.85	21	19

Stephen M. Scala  
(617) 946-3923

Ian C. Sanderson  
(617) 946-3922

Jonathan R. Moran, CFA  
(617) 946-3755

Kenneth C. Cacciatore  
(617) 946-3968

Jean B. Perreault  
(617) 946-3967

- The majority of pharmaceutical sales for the treatment of urinary incontinence are in the United States. International sales are anticipated to accelerate over the next few years as physician awareness increases.

**ESTIMATED U.S. MARKET FOR URINARY INCONTINENCE (UI) DRUGS\***

	2000	2001E	2002E	2003E	2004E	2005E	CGR	Comment
<b>U.S. Patient Population/Prescriptions (000's)</b>								
Overactive Bladder Sufferers	17,955	18,475	19,050	19,640	20,230	20,835	+3%	- 17MM+ Americans with overactive bladder,
% Growth	+3%	+3%	+3%	+3%	+3%	+3%		13MM+ Americans w/ UI (1MM overflow UI,
% With Urge UI Symptoms	30%	30%	30%	30%	30%	30%		4MM stress UI, 3MM urge UI, 5MM mixed UI)
Urge UI Sufferers	5,385	5,545	5,715	5,890	6,070	6,250	+3%	- Includes portion of patients with mixed UI
% UUI Patients Seeking Treatment	36%	40%	44%	47%	48%	49%		- Assumes 36-38% of patients now seek treatment
UUI Patients Seeking Treatment	1,960	2,220	2,490	2,780	2,915	3,045	+9%	
Drug Therapy Market Share	38%	42%	45%	53%	63%	73%		- NAFC survey (100K members) showed 50%+
UUI Patients Seeking Drug Tx	745	920	1,110	1,485	1,835	2,225	+24%	
% UUI Patients On Drug Therapy	14%	17%	19%	25%	30%	36%		
<b>Number of Scripts Filled/Year</b>	<b>8,940</b>	<b>11,040</b>	<b>13,431</b>	<b>17,820</b>	<b>22,020</b>	<b>26,700</b>	<b>+24%</b>	<b>- Assumes all patients compliant</b>
<b>% Growth</b>	<b>+28%</b>	<b>+23%</b>	<b>+22%</b>	<b>+33%</b>	<b>+24%</b>	<b>+21%</b>		<b>- Aggressive marketing improving diagnosis</b>
<b>Detrol LA (PHA) Market Share</b>								
Prescriptions (000's)		15%	34%	39%	40%	40%		- Once-daily LA launched 1/01
% Growth								- Improved side-effect profile compared to Detrol
Price Therapy/Day		\$2.80	\$2.80	\$2.80	\$2.80	\$2.80		- 2,100+ U.S. reps detail
Price/Prescription		\$84.00	\$84.00	\$84.00	\$84.00	\$84.00		- Priced at par with standard Detrol
<b>Detrol LA Sales (\$MM)</b>		<b>\$140</b>	<b>\$380</b>	<b>\$580</b>	<b>\$740</b>	<b>\$900</b>	<b>NA</b>	
<b>Darifenacin (PFE) Market Share</b>								
Prescriptions (000's)				13%	21%	25%		- In Phase III; NDA '02E; assumes early '03 launch
% Growth								
Price Therapy/Day				\$2.80	\$2.80	\$2.80		
Price/Prescription				\$84.00	\$84.00	\$84.00		- Assumes priced at par with Detrol/LA
<b>Darifenacin Sales (\$MM)</b>				<b>\$200</b>	<b>\$380</b>	<b>\$550</b>	<b>NA</b>	
<b>Ditropan XL (JNJ/AZA) Market Share</b>								
Prescriptions (000's)	24%	27%	29%	25%	23%	21%		- Pfizer's Darifenacin and Watson's Oxytrol clip
% Growth	+124%	+38%	+33%	+12%	+14%	+12%		- Launched 2/99 for overactive bladder
Price Therapy/Day	\$2.75	\$2.75	\$2.75	\$2.75	\$2.75	\$2.75		- JNJ/ALZA, UCB Pharma and Bayer co-promotion
Price/Prescription	\$82.50	\$82.50	\$82.50	\$82.50	\$82.50	\$82.50		- 1,200+ U.S. reps detail
<b>Ditropan XL Sales (\$MM)</b>	<b>\$179</b>	<b>\$245</b>	<b>\$325</b>	<b>\$365</b>	<b>\$415</b>	<b>\$465</b>	<b>+21%</b>	
<b>Detrol (PHA) Market Share</b>								
Prescriptions (000's)	48%	39%	21%	11%	6%	4%		- Conversion to once-daily beginning in 2001
% Growth	+22%	-0%	-33%	-33%	-25%	-34%		
Price Therapy/Day	\$2.50	\$2.80	\$2.80	\$2.80	\$2.80	\$2.80		
Price/Prescription	\$75.00	\$84.00	\$84.00	\$84.00	\$84.00	\$84.00		
<b>Detrol Sales (\$MM)</b>	<b>\$324</b>	<b>\$360</b>	<b>\$240</b>	<b>\$160</b>	<b>\$120</b>	<b>\$80</b>	<b>-24%</b>	- Likely will remain dominant franchise with LA
<b>Oxytrol Patch (WPI) Market Share</b>								
Prescriptions (000's)			2%	5%	5%	5%		- Oxybutynin patch; improved side-effect profile
% Growth								- Marketed by Women's Health and GP Division
Price/Prescription			\$80.00	\$80.00	\$80.00	\$80.00		combined 400E U.S. reps to detail
<b>Oxybutynin TD Patch Sales (\$MM)</b>			<b>\$25</b>	<b>\$70</b>	<b>\$85</b>	<b>\$100</b>	<b>NA</b>	
<b>Duloxetine (LLY) Market Share</b>								
Prescriptions (000's)				1%	2%	2%		- Eli Lilly
% Growth								- Stress urinary incontinence; limited efficacy
Price Therapy/Day				\$2.75	\$2.75	\$2.75		
Price/Prescription				\$82.50	\$82.50	\$82.50		
<b>Duloxetine Sales (\$MM)</b>				<b>\$15</b>	<b>\$30</b>	<b>\$50</b>	<b>NM</b>	- Assumes NDA filed in 2002
<b>Oxybutynin Market Share</b>								
Prescriptions (000's)	26%	18%	13%	6%	4%	3%		- Share decline with launch of new therapies
% Growth	-5%	-15%	-15%	-32%	-26%	+0%		
Price/Prescription	\$17.50	\$17.50	\$17.50	\$17.50	\$17.50	\$17.50		
<b>Oxybutynin Generics Sales (\$MM)</b>	<b>\$41</b>	<b>\$35</b>	<b>\$30</b>	<b>\$20</b>	<b>\$15</b>	<b>\$10</b>	<b>-25%</b>	
<b>Other Therapies Sales (\$MM)</b>								
	<b>\$10</b>	<b>\$15</b>	<b>\$20</b>	<b>\$25</b>	<b>\$30</b>	<b>\$35</b>	<b>NA</b>	<b>- Various others</b>
<b>Total Incontinence Drug Sales (\$MM)</b>								
	<b>\$560</b>	<b>\$800</b>	<b>\$1,025</b>	<b>\$1,440</b>	<b>\$1,815</b>	<b>\$2,195</b>	<b>+31%</b>	<b>- Improved treatments, better compliance</b>
<b>% Growth</b>	<b>+37%</b>	<b>+43%</b>	<b>+28%</b>	<b>+40%</b>	<b>+26%</b>	<b>+21%</b>		<b>(Market sales include generics)</b>

Source: SG Cowen estimates, IMS America.

\* Patient population and scripts in 000's; sales in \$MM.

# Notes

This publication is issued in the United Kingdom by or through SG Securities (London) Ltd ("SGSL") which is regulated by The Securities and Futures Authority and distributed by SG Securities (HK) Limited, SG Securities Asia (London) Limited and SG Securities (Singapore) Pte Limited, which are regulated by The Securities and Futures Commission, The Securities and Futures Authority and the Monetary Authority of Singapore, respectively and hereinafter referred to as the "Distributors." It is not intended to be an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities. The information contained herein, including any expression of opinion, has been obtained from or is based upon sources believed to be reliable but is not guaranteed as to accuracy or completeness although SGSL and the Distributors believe it to be fair and not misleading. SGSL, the Distributors, and their affiliated companies in the Société Générale Group, may from time to time deal in, hold or act as market-makers or act as advisers, brokers or bankers in relation to the securities, or derivatives thereof, of persons, firms or entities mentioned in this document or be represented on the board of such persons, firms or entities. Employees of SGSL, the Distributors and their affiliated companies in the Société Générale Group, or individuals connected to them, may from time to time have a position in or be holding any of the investments or related investments mentioned in this document. SGSL, the Distributors and their affiliated companies in the Société Générale Group, are under no obligation to disclose or take account of this document when advising or dealing with or for their customers and may have acted upon or made use of the information in this document prior to its publication. Any investments or investment services mentioned herein are not available for private customers.

**Notice to US Investors:** This research report is distributed in the United States by SG Cowen Securities Corporation, a US registered broker-dealer, which accepts responsibility for its contents. Any US person receiving this report and wishing to effect transactions in any security discussed herein should do so with or through SG Cowen Securities Corporation to conform with the requirements of US securities laws.

Copyright The Société Générale Group 2001. All rights reserved.

SG Cowen Securities Corporation makes a market in AMGN.

## SG Cowen

<b>New York</b>	(212) 278-6000	<b>London</b>	44-207-710-0900
	(212) 495-6000	<b>Geneva</b>	41-22-707-6900
<b>Boston</b>	(617) 946-3700	<b>Paris</b>	33-1-42-13-55-00
<b>San Francisco</b>	(415) 646-7200	<b>Toronto</b>	(416) 362-2229
<b>Chicago</b>	(312) 516-4690	<b>Zurich</b>	41-1-225-2040
<b>Cleveland</b>	(440) 331-3531		
<b>Dallas</b>	(214) 979-2735		

**Further information on any of the above securities may be obtained from our offices.** This report is published solely for information purposes, and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state where such an offer or solicitation would be illegal. The information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a complete statement or summary of the available data. Any opinions expressed herein are statements of our judgment on this date and are subject to change without notice. Portions of this report may have been previously disseminated by our affiliated companies in the Société Générale Group. SG Cowen Securities Corporation, or one or more of its employees, including the writer of this report, may have a position in any of the securities discussed herein. The contents and appearance of